ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Tvardi Therapeutics Inc
3.64
+0.0500
1.39%
盤後:
3.64
0.0000
0.00%
16:10 EST
成交量:
3.85萬
成交額:
14.06萬
市值:
3,414.81萬
市盈率:
-0.46
高:
3.74
開:
3.57
低:
3.55
收:
3.59
52周最高:
43.65
52周最低:
3.50
股本:
938.13萬
流通股本:
777.87萬
量比:
0.78
換手率:
0.50%
股息:
- -
股息率:
- -
每股收益(TTM):
-7.8700
每股收益(LYR):
-4.5947
淨資產收益率:
-135.64%
總資產收益率:
-72.68%
市淨率:
1.23
市盈率(LYR):
-0.79
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Tvardi Therapeutics Inc 新一代STAT3抑制劑Tti-109一期臨牀健康受試者頂線數據預計2026年上半年公布
美股速递
·
01/08
Tvardi Therapeutics計劃於2026年上半年發布Tti-101在肝細胞癌(HCC)二期試驗中的主要數據
美股速递
·
2025/11/14
Tvardi Therapeutics Inc:Piper Sandler將評級從增持下調至中性,目標價從78美元下調至4美元
美股速递
·
2025/10/13
嗡嗡聲--美國股票走勢-Bloom Energy、Argan、Endra Life Sciences
路透中文
·
2025/10/13
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/TVRD"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":3.64,"timestamp":1771621200000,"preClose":3.59,"halted":0,"volume":38544,"hourTrading":{"tag":"盘后","latestPrice":3.64,"preClose":3.64,"latestTime":"16:10 EST","volume":124,"amount":451.36,"timestamp":1771621804647,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.013927576601671383,"floatShares":7778729,"shares":9381344,"eps":-7.87,"marketStatus":"休市中","change":0.05,"latestTime":"02-20 16:00:00 EST","open":3.57,"high":3.735,"low":3.55,"amount":140607.4253,"amplitude":0.051532,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.87,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":3.59,"preHourTrading":{"tag":"盘前","latestPrice":3.5501,"preClose":3.59,"latestTime":"08:00 EST","volume":142,"amount":504.1071,"timestamp":1771592402115,"change":-0.0399,"changeRate":-0.011114,"amplitude":0.000028},"postHourTrading":{"tag":"盘后","latestPrice":3.64,"preClose":3.64,"latestTime":"16:10 EST","volume":124,"amount":451.36,"timestamp":1771621804647,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7812709030100334,"impliedVol":0.061,"impliedVolPercentile":0.0177},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":7778729,"roa":"-72.68%","roe":"-135.64%","lyrEps":-4.594733,"volumeRatio":0.7812709030100334,"shares":9381344,"dividePrice":0,"high":3.735,"amplitude":0.051532,"preClose":3.59,"low":3.55,"week52Low":3.5,"pbRate":"1.23","week52High":43.65,"institutionHeld":0,"latestPrice":3.64,"eps":-7.87,"divideRate":0,"volume":38544,"delay":0,"ttmEps":-7.87,"open":3.57,"prevYearClose":4.3,"prevWeekClose":3.72,"prevMonthClose":3.97,"prevQuarterClose":4.3,"fiveDayClose":3.72,"twentyDayClose":4.83,"sixtyDayClose":3.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"TVRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.83,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2025-08-14","symbol":"TVRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":1},{"market":"US","date":"2025-05-13","symbol":"TVRD","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-3.22},{"market":"US","date":"2025-04-16","symbol":"TVRD","defaultRemindTime":1744810200000,"type":"split","dateTimestamp":1744776000000,"forFactor":3,"toFactor":1,"ratio":3},{"market":"US","date":"2025-03-11","symbol":"TVRD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.25,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":8,"updateTime":1770267600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVRD","date":"2026-02-20","current":-0.462516,"percent":0.993007,"low":-17.054928,"twenty":-11.810677,"median":-1.847154,"eighty":-1.590139,"high":-1.408431,"avg":-5.497508,"sd":5.248359,"marketCap":33679024},"quantilePoints":[{"date":"2025-08-01","current":-6.984237,"twenty":-7.018674,"median":-6.984237,"eighty":-6.867475,"marketCap":242869870},{"date":"2025-08-08","current":-6.220168,"twenty":-7.05634,"median":-6.986928,"eighty":-6.651705,"marketCap":216300131},{"date":"2025-08-15","current":-6.400424,"twenty":-7.003609,"median":-6.690985,"eighty":-6.397734,"marketCap":222568344},{"date":"2025-08-22","current":-10.573024,"twenty":-9.576632,"median":-6.986928,"eighty":-6.42948,"marketCap":249861702},{"date":"2025-08-29","current":-12.013447,"twenty":-10.759129,"median":-7.048807,"eighty":-6.480866,"marketCap":283901784},{"date":"2025-09-05","current":-12.078921,"twenty":-11.588463,"median":-7.134899,"eighty":-6.493511,"marketCap":285449060},{"date":"2025-09-12","current":-14.047103,"twenty":-11.928926,"median":-9.803211,"eighty":-6.612426,"marketCap":331961128},{"date":"2025-09-19","current":-15.372451,"twenty":-12.457478,"median":-10.666275,"eighty":-6.823352,"marketCap":363281754},{"date":"2025-09-26","current":-14.606606,"twenty":-13.432046,"median":-11.499578,"eighty":-6.955181,"marketCap":345183308},{"date":"2025-10-03","current":-14.82882,"twenty":-14.620891,"median":-11.737664,"eighty":-6.987466,"marketCap":350434671},{"date":"2025-10-10","current":-17.054928,"twenty":-14.850248,"median":-11.943013,"eighty":-6.991233,"marketCap":403042070},{"date":"2025-10-17","current":-2.571334,"twenty":-14.850248,"median":-11.769409,"eighty":-6.823352,"marketCap":60765765},{"date":"2025-10-24","current":-2.047544,"twenty":-14.833582,"median":-11.58886,"eighty":-6.422216,"marketCap":48387554},{"date":"2025-10-31","current":-1.849138,"twenty":-14.74787,"median":-11.130543,"eighty":-4.843171,"marketCap":43698837},{"date":"2025-11-07","current":-1.563435,"twenty":-14.662953,"median":-10.195062,"eighty":-2.595143,"marketCap":36947086},{"date":"2025-11-14","current":-1.631573,"twenty":-14.620891,"median":-9.523459,"eighty":-2.06421,"marketCap":38557323},{"date":"2025-11-21","current":-1.515552,"twenty":-14.489944,"median":-7.06764,"eighty":-1.887232,"marketCap":35836734},{"date":"2025-11-28","current":-1.634574,"twenty":-14.266143,"median":-6.990963,"eighty":-1.811838,"marketCap":38651137},{"date":"2025-12-05","current":-1.658378,"twenty":-13.805842,"median":-6.911597,"eighty":-1.667399,"marketCap":39214017},{"date":"2025-12-12","current":-1.781368,"twenty":-13.436014,"median":-6.493242,"eighty":-1.662637,"marketCap":42122234},{"date":"2025-12-19","current":-1.543324,"twenty":-13.412999,"median":-6.400424,"eighty":-1.660082,"marketCap":36493428},{"date":"2025-12-26","current":-1.5949,"twenty":-13.32332,"median":-6.349307,"eighty":-1.639335,"marketCap":37713002},{"date":"2026-01-02","current":-1.705987,"twenty":-13.031267,"median":-2.777676,"eighty":-1.642509,"marketCap":40339779},{"date":"2026-01-09","current":-1.678216,"twenty":-12.62652,"median":-2.62292,"eighty":-1.634574,"marketCap":39683085},{"date":"2026-01-16","current":-1.789303,"twenty":-12.344784,"median":-2.448323,"eighty":-1.634574,"marketCap":42309861},{"date":"2026-01-23","current":-1.91626,"twenty":-12.181298,"median":-2.07532,"eighty":-1.634574,"marketCap":45311891},{"date":"2026-01-30","current":-1.547291,"twenty":-12.091222,"median":-1.95231,"eighty":-1.634574,"marketCap":36587241},{"date":"2026-02-06","current":-1.408431,"twenty":-12.026542,"median":-1.896756,"eighty":-1.617117,"marketCap":33303771},{"date":"2026-02-13","current":-1.475877,"twenty":-11.900753,"median":-1.8627,"eighty":-1.598129,"marketCap":34898599},{"date":"2026-02-20","current":-1.424301,"twenty":-11.810677,"median":-1.847154,"eighty":-1.590139,"marketCap":33679024}],"updateTime":1771767323986},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVRD\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1153510288","title":"Tvardi Therapeutics Inc 新一代STAT3抑制劑Tti-109一期臨牀健康受試者頂線數據預計2026年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1153510288","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153510288?lang=zh_tw&edition=fundamental","pubTime":"2026-01-08 21:13","pubTimestamp":1767878002,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc宣布,其新一代STAT3抑制剂Tti-109的一期临床试验取得重要进展。针对健康志愿者的顶线数据收集工作正按计划推进,预计将于2026年上半年完成。\n该研究旨在评估Tti-109的安全性、耐受性及药代动力学特征。STAT3作为关键信号传导蛋白,在多种肿瘤生长中扮演核心角色。Tti-109通过精准抑制STAT3活性,为晚期癌症治疗提供了新思路。\n目前临床试验进程符合预期时间表。若数据结果达到预设终点,将为后续针对实体瘤和血液恶性肿瘤的二期研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"1175189763","title":"Tvardi Therapeutics計劃於2026年上半年發布Tti-101在肝細胞癌(HCC)二期試驗中的主要數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1175189763","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175189763?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 05:26","pubTimestamp":1763069193,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics计划于2026年上半年发布Tti-101在肝细胞癌(HCC)二期试验中的主要数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"1133823913","title":"Tvardi Therapeutics Inc:Piper Sandler將評級從增持下調至中性,目標價從78美元下調至4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133823913","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133823913?lang=zh_tw&edition=fundamental","pubTime":"2025-10-13 22:06","pubTimestamp":1760364390,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc:Piper Sandler将评级从增持下调至中性,目标价从78美元下调至4美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2575740111","title":"嗡嗡聲--美國股票走勢-Bloom Energy、Argan、Endra Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2575740111","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575740111?lang=zh_tw&edition=fundamental","pubTime":"2025-10-13 21:14","pubTimestamp":1760361263,"startTime":"0","endTime":"0","summary":"nL3N3VU0QT ** Argan SA AGX.N:BUZZ - 在摩根大通将其评级上调至 \"增持 \"后上涨 nL6N3VU0HO ** Abeona Therapeutics Inc ABEO.O:BUZZ - 因美国 FDA 将其眼病基因疗法选入试点项目而上涨 nL3N3VU0RT ** Bicara Therapeutic Inc BCAX.O:BUZZ - 在美国 FDA 授予其癌症疗法 \"突破性 \"标签后上涨 nL3N3VU0T8 ** Endra Life Sciences Inc NDRA.O:BUZZ - 在获得490万美元融资后暴涨 nL3N3VU0TG ** Ryanair Holdings PLC RYAAY.O:BUZZ - 巴克莱继续看好廉价航空公司而非传统竞争对手。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL3S3VU0W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689514.USD","AGX","DVN","ABEO","STUB","LU2168564222.USD","NEM","LU2129689431.USD","LU0345769631.USD","BCAX","RIO.AU","SCCO","COP","LU0320765489.SGD","BE","FAST","LU0256863902.USD","LU0345780521.USD","LU1894683348.USD","LNT","BHP.AU","NDRA","TVRD","ALK","PGEN","BK4533","LU1066051498.USD","LU0738911758.USD","LU0949170426.SGD","MACW.SI","LU2065169927.USD","LU1119994496.HKD","LU2023250843.SGD","RIO.UK","CVX","IE000KEQY171.SGD","XOM","LU2168564065.EUR","LU0215105999.USD","BYND","LU2129689605.HKD","AU"],"gpt_icon":1}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TVRD\",params:#limit:6,delay:false,,,undefined,":[]}}